Original language | English (US) |
---|---|
Pages (from-to) | 1349-1358 |
Number of pages | 10 |
Journal | Journal of Allergy and Clinical Immunology |
Volume | 119 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2007 |
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Allergy and Clinical Immunology, Vol. 119, No. 6, 06.2007, p. 1349-1358.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - American Academy of Allergy, Asthma & Immunology Work Group Report
T2 - Exercise-induced asthma
AU - Weiler, John M.
AU - Bonini, Sergio
AU - Coifman, Robert
AU - Craig, Timothy
AU - Delgado, Luís
AU - Capão-Filipe, Miguel
AU - Passali, Desiderio
AU - Randolph, Christopher
AU - Storms, William
N1 - Funding Information: S.B. is in part supported by grants from the Italian Ministry of Health, Commission for Vigilance and Doping, the Italian Institute of Health, and the European Commission Network of Excellence GA 2 LEN-FOOD-CT-2004-506378. Funding Information: Disclosure of potential conflict of interest: J. M. Weiler owns stock in, has patent licensing arrangements with, and is employed by CompleWare Corporation and Iowa Clinical Research Corporation. S. Bonini has consulting arrangements with Lofarma, Almirall, and Pfizer; has received grant support from Almirall, Bioallergy, Lofarma, and Schering-Plough; is employed as a member of the Research and Development Commission of the Italian Drug Agency; and is on the speakers' bureau for Alcon, Allergopharma, Allergy Therapeutics, ALK-Albelló, Almirall, Aventis, Sanofi-Synthelabo, Stallergens, UCB, and Zambon. R. Coifman is employed by Allergy and Asthma of South Jersey. D. Passali has consulting arrangements with Lofarma, Sanofi-Aventis, and Angelini and is on the speakers' bureau for Schering-Plough, Valeas, GlaxoSmithKline, Mercury, and Amplifon. C. Randolph is on the speakers' bureau for GlaxoSmithKline, Schering-Plough, Novartis, Genentech, Merck, and AstraZeneca. W. Storms has consulting arrangements with Adams, Alco, Altana, AstraZeneca, Consumer Reports/Consumer Union, Efficas, Exaeris, Genentech, Greer, GlaxoSmithkline, Hoffman, Laroche, Inspire, Isis, Ivax, King, Medpointe, Merck, Nexcura, Novartis, Sanofi-Aventis, Schering-Plough, Sepracor, Strategic Biosciences, Strategic Pharmaceutical Advisors, TREAT Foundation, and Wyeth; owns stock in Strategic Biosciences, Strategic Pharmaceutical Advisors, and Exaeris; has patent licensing arrangements with Strategic Biosciences; has received grant support from Alcon, Altana, AstraZeneca, BMS, Genentech, GlaxoSmithKline, Medpointe, Merck, Novartis, Sanofi-Aventis, and Schering-Plough; and is on the speakers' bureau for Abbott, Alco, AstraZeneca, Genentech, Medpointe, Merck, Novartis, Pfizer, Sanofi-Aventis, and Schering-Plough. The other authors have declared that they have no conflict of interest.
PY - 2007/6
Y1 - 2007/6
UR - http://www.scopus.com/inward/record.url?scp=34249808197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249808197&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2007.02.041
DO - 10.1016/j.jaci.2007.02.041
M3 - Article
C2 - 17433829
AN - SCOPUS:34249808197
SN - 0091-6749
VL - 119
SP - 1349
EP - 1358
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 6
ER -